Brief: Mineralys Therapeutics Inc Says Lorundrostat Shows 16.9 Mmhg Reduction At Week 6, 19.0 Mmhg At Week 12
24/05/2025 09:35
May 24 (Reuters) - Mineralys Therapeutics Inc MLYS.O: MINERALYS THERAPEUTICS INC - LORUNDROSTAT SHOWS 16.9 MMHG REDUCTION AT WEEK 6, 19.0 MMHG AT WEEK 12 MINERALYS THERAPEUTICS INC - LORUNDROSTAT SAFETY PROFILE SHOWS MODEST, REVERSIBLE EFFECTS ON ELECTROLYTES MINERALYS THERAPEUTICS INC - TRIAL MET ENDPOINTS WITH SIGNIFICANT BLOOD PRESSURE REDUCTION Source text: ID:nGNX7SCFDs Further company coverage: MLYS.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mineralys Therapeutics
See all newsBrief: Mineralys Therapeutics Expands Its Board Of Directors With The Appointments Of Kristine Peterson And Lonnel Coats
Mineralys Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)
U.S. STOCKS ON THE MOVE-Medtronic, Macy's, USA Rare Earth
U.S. STOCKS ON THE MOVE-USA Rare Earth, MiniMed, Rent the Runway